How to manage aspergillosis in non-neutropenic intensive care unit patients

Massimo Antonelli, Matteo Bassetti, Elda Righi, Raffaele De Gaudio, Antonino Giarratano, Tereesita Mazzei, Giulia Morace, Nicola Petrosillo, Stefania Stefani

Research output: Contribution to journalArticle

31 Citations (Scopus)


Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level of suspicion and prompt initiation of adequate antifungal treatment are mandatory. Epidemiology, risk factors, diagnostic algorithms, and different approaches in antifungal therapy for invasive aspergillosis in non-neutropenic patients are reviewed.
Original languageEnglish
Pages (from-to)458-458
Number of pages1
JournalCritical Care
Publication statusPublished - 2014


  • Adrenal Cortex Hormones
  • Antifungal Agents
  • Aspergillosis
  • Communicable Diseases, Emerging
  • Critical Illness
  • Humans
  • Immunocompromised Host
  • Incidence
  • Intensive Care Units
  • Opportunistic Infections
  • Prevalence
  • Prognosis
  • Pulmonary Disease, Chronic Obstructive
  • Risk Factors


Dive into the research topics of 'How to manage aspergillosis in non-neutropenic intensive care unit patients'. Together they form a unique fingerprint.

Cite this